Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeffrey Mark Brill
Observed names:
J. Brill,
Jeffrey M. Brill
Institution:
Galera Therapeutics, Inc. (United States)
Observed institutions:
Cancer Care Northwest,
New York Oncology Hematology,
Rocky Mountain Cancer Centers,
Galera Therapeutics, Inc. (United States)
OpenAlex ID:
A5021815203
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
2019
·
Carryn M. Anderson
, Christopher M. Lee
, et al.
·
Journal of Clinical Oncology
·
132
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma
2017
·
Carryn M. Anderson
, Stephen T. Sonis
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
87
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
2015
·
Herbert I. Hurwitz
, David C. Smith
, et al.
·
Cancer Chemotherapy and Pharmacology
·
83
PDF
Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study
2015
·
John F. DiPersio
, Harry P. Erba
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
47
An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL)
2009
·
E. Kingsley
, D. Richards
, et al.
·
Journal of Clinical Oncology
·
11
Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC)
2016
·
C.M. Anderson
, B.G. Allen
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
7
PDF
Roman: Reduction in oral mucositis with avasopasem manganese (GC4419)—Phase 3 trial in patients receiving chemoradiotherapy for locally-advanced, non-metastatic head and neck cancer.
2019
·
Jon Holmlund
, Jeffrey Mark Brill
, et al.
·
Journal of Clinical Oncology
·
5
Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP).
2018
·
Carryn M. Anderson
, Christopher M Lee
, et al.
·
Journal of Clinical Oncology
·
5
Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).
2016
·
Carryn M. Anderson
, Bryan G. Allen
, et al.
·
Journal of Clinical Oncology
·
3
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
2014
·
Herbert Hurwitz
, Henry Clement Pitot
, et al.
·
Journal of Clinical Oncology
·
3
76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas
2012
·
H. Hurwitz
, H. Pitot
, et al.
·
European Journal of Cancer
·
3
2-Year Outcomes Of Phase Iib, Randomized, Double-Blind Trial Of GC4419 Versus Placebo To Reduce Severe Oral Mucositis Due To Concurrent Radiotherapy And Cisplatin For Head And Neck Cancer
2020
·
C.M. Anderson
, C.M. Lee
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
2
PDF
ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–Phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.
2020
·
Jon Holmlund
, Jeffrey Mark Brill
, et al.
·
Journal of Clinical Oncology
·
2
A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients (pts) with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)
2018
·
C.M. Anderson
, C. Lee
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
2
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
2014
·
John F. DiPersio
, Harry Paul Erba
, et al.
·
Journal of Clinical Oncology
·
2
Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
2020
·
C.M. Anderson
, C.M. Lee
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
1
Phase 1b Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy (CRT)-Induced Oral Mucositis (OM) in Patients (pts) With Oral Cavity or Oropharyngeal Carcinoma (OCC)
2016
·
C.M. Anderson
, B.G. Allen
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
1
PDF
CLO19-037: Reducing the Duration, Incidence and Severity of Mucosal Injury Due to Cancer Radiation therapy (RT); Positive Randomized Phase 2b Trial Results With GC4419 (Avasopasem Manganese), a Small Molecule Superoxide (SO) Dismutase (SOD) Mimetic
2019
·
Jon T. Holmlund
, Carryn M. Anderson
, et al.
·
Journal of the National Comprehensive Cancer Network
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
2015
·
Henry C. Pitot
, Herbert Hurwitz
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
19
Citation count:
396
H-index:
6
I10-index:
5
Year
Topic
Type